Studie - Menopausal Disorders – Pipeline Review, H1 2012

Menopausal Disorders — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Menopausal Disorders - Pipeline Review, H1 2012', provides an overview of the Menopausal Disorders therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. 'Menopausal Disorders - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Menopausal Disorders.
- A review of the Menopausal Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Menopausal Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Menopausal Disorders pipeline depth and focus of Menopausal Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Menopausal Disorders Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Menopausal Disorders 9

Menopausal Disorders Therapeutics under Development by Companies 11

Menopausal Disorders Therapeutics under Investigation by Universities/Institutes 14

Late Stage Products 16

Comparative Analysis 16

Mid Clinical Stage Products 17

Comparative Analysis 17

Early Clinical Stage Products 18

Comparative Analysis 18

Menopausal Disorders Therapeutics — Products under Development by Companies 19

Menopausal Disorders Therapeutics — Products under Investigation by Universities/Institutes 20

Companies Involved in Menopausal Disorders Therapeutics Development 21

Amgen Inc. 21

Merck & Co., Inc. 22

Ablynx 23

Arkopharma SA 24

Chiesi Farmaceutici SpA 25

Depomed, Inc. 26

Noven Pharmaceuticals, Inc. 27

Pfizer Inc. 28

Zosano Pharma, Inc. 29

Osteologix, Inc. 30

Paladin Labs Inc. 31

Bionovo, Inc. 32

Unigene Laboratories, Inc. 33

Acceleron Pharma, Inc. 34

Pantarhei Bioscience BV 35

EffRx, Inc. 36

Radius Health, Inc. 37

Meditrina Pharmaceuticals, Inc. 38

DSM Nutritional Products AG 39

Lipocine Inc. 40

Tarsa Therapeutics, Inc. 41

Pherin Pharmaceuticals, Inc. 42

Ausio Pharmaceuticals, LLC 43

Menopausal Disorders — Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Combination Products 45

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

AMG 785 - Drug Profile 50

Odanacatib - Drug Profile 51

Serada - Drug Profile 53

Mesafem - Drug Profile 54

Sotatercept - Drug Profile 56

RAD1901 - Drug Profile 58

Steovess - Drug Profile 60

Estetrol - Drug Profile 61

Ellavie - Drug Profile 63

Estradiol + Testosterone Gel - Drug Profile 64

Menerba - Drug Profile 65

Seala - Drug Profile 67

NB S101 - Drug Profile 68

PTH Analogs Oral - Drug Profile 69

OSTORA - Drug Profile 70

Aprela - Drug Profile 72

Femathina - Drug Profile 74

ALX-0141 - Drug Profile 75

AUS-131 - Drug Profile 76

Parathyroid Hormone-Related Protein (1-36) - Drug Profile 78

Fablyn - Drug Profile 80

CHF4227 - Drug Profile 82

Denosumab + Teriparatide - Drug Profile 83

ZP-PTH - Drug Profile 84

Zosano PTH - Drug Profile 85

Acupuncture + Gabapentin - Drug Profile 86

Bonviva - Drug Profile 87

Actonel - Drug Profile 88

Fosamax - Drug Profile 89

Cyclophosphamide + Goserelin - Drug Profile 90

Pregabalin - Drug Profile 92

Megestrol Acetate - Drug Profile 93

Pristiq - Drug Profile 94

Black Cohosh - Drug Profile 96

Citalopram hydrobromide - Drug Profile 98

PF-04427429 - Drug Profile 99

CDB-2914 - Drug Profile 100

Prometrium - Drug Profile 102

Estradiol + Progesterone - Drug Profile 103

Estradiol + Estriol + Progesterone - Drug Profile 104

Estradiol + Medroxyprogesterone acetate - Drug Profile 105

Danggui Buxue Tang - Drug Profile 106

Estradiol - Drug Profile 107

BA058 - Drug Profile 108

Phyto Soya Vaginal Gel - Drug Profile 110

Denosumab + Alendronate - Drug Profile 112

PTH 1-34 + Fluoride - Drug Profile 113

PTH 1-34 - Drug Profile 114

Fluoride - Drug Profile 115

Ostora - Drug Profile 116

PH80-HF - Drug Profile 118

Nelfinavir + NRTIs + Estradiol + Medroxyprogesterone acetate - Drug Profile 119

Gabapentin - Drug Profile 121

LPCN 1002 - Drug Profile 122

Menopausal Disorders Therapeutics — Drug Profile Updates 123

Menopausal Disorders Therapeutics — Discontinued Products 138

Menopausal Disorders Therapeutics - Dormant Products 139

Menopausal Disorders — Product Development Milestones 142

Featured News & Press Releases 142

Appendix 150

Methodology 150

Coverage 150

Secondary Research 150

Primary Research 150

Expert Panel Validation 150

Contact Us 151

Disclaimer 151





List of Tables

Number of Products Under Development for Menopausal Disorders, H1 2012 13

Products under Development for Menopausal Disorders — Comparative Analysis, H1 2012 14

Number of Products under Development by Companies, H1 2012 16

Number of Products under Development by Companies, H1 2012 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2012 19

Comparative Analysis by Late Stage Development, H1 2012 20

Comparative Analysis by Mid Clinical Stage Development, H1 2012 21

Comparative Analysis by Early Clinical Stage Development, H1 2012 22

Products under Development by Companies, H1 2012 23

Products under Investigation by Universities/Institutes, H1 2012 24

Amgen Inc., H1 2012 25

Merck & Co., Inc., H1 2012 26

Ablynx, H1 2012 27

Arkopharma SA, H1 2012 28

Chiesi Farmaceutici SpA, H1 2012 29

Depomed, Inc., H1 2012 30

Noven Pharmaceuticals, Inc., H1 2012 31

Pfizer Inc., H1 2012 32

Zosano Pharma, Inc., H1 2012 33

Osteologix, Inc., H1 2012 34

Paladin Labs Inc., H1 2012 35

Bionovo, Inc., H1 2012 36

Unigene Laboratories, Inc., H1 2012 37

Acceleron Pharma, Inc., H1 2012 38

Pantarhei Bioscience BV, H1 2012 39

EffRx, Inc., H1 2012 40

Radius Health, Inc., H1 2012 41

Meditrina Pharmaceuticals, Inc., H1 2012 42

DSM Nutritional Products AG, H1 2012 43

Lipocine Inc., H1 2012 44

Tarsa Therapeutics, Inc., H1 2012 45

Pherin Pharmaceuticals, Inc., H1 2012 46

Ausio Pharmaceuticals, LLC, H1 2012 47

Assessment by Monotherapy Products, H1 2012 48

Assessment by Combination Products, H1 2012 49

Assessment by Stage and Route of Administration, H1 2012 51

Assessment by Stage and Molecule Type, H1 2012 53

Menopausal Disorders Therapeutics — Drug Profile Updates 127

Menopausal Disorders Therapeutics — Discontinued Products 142

Menopausal Disorders Therapeutics — Dormant Products 143

Menopausal Disorders Therapeutics — Dormant Products (Contd..1) 144

Menopausal Disorders Therapeutics — Dormant Products (Contd..2) 145





List of Figures

Number of Products under Development for Menopausal Disorders, H1 2012 13

Products under Development for Menopausal Disorders — Comparative Analysis, H1 2012 14

Products under Development by Companies, H1 2012 15

Products under Investigation by Universities/Institutes, H1 2012 18

Late Stage Products, H1 2012 20

Mid Clinical Stage Products, H1 2012 21

Early Clinical Stage Products, H1 2012 22

Assessment by Monotherapy Products, H1 2012 48

Assessment by Combination Products, H1 2012 49

Assessment by Route of Administration, H1 2012 50

Assessment by Stage and Route of Administration, H1 2012 51

Assessment by Molecule Type, H1 2012 52

Assessment by Stage and Molecule Type, H1 2012 53

• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012
• Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
• Endometriosis Global Clinical Trials Review, H2, 2012
• Primary Dysmenorrhea – Pipeline Review, H2 2012